Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/158439
Insulin-mimetic compound hexaquis (benzylammonium) decavanadate is antilipolytic in human fat cells
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
This study investigates in murine and human adipocytes the antilipolytic properties of a conjugate of benzylamine and decavanadate (B6V10), already reported to lower hyperglycaemia in diabetic rodents. Data indicated that the conjugate dose-dependently inhibited submaximal activation of lipolysis in all the species studied. Such antilipolytic action deals with the in vivo FFA-lowering properties already described for B6V10 in diabetic rats. B6V10 also activated lipogenesis and glucose transport in fat cells. B6V10 should therefore be useful in preventing the lipotoxicity constituted by the unrestrained lipolytic activity of insulin-resistant adipocytes in obese individuals presenting type 2 diabetes, a state named diabesity.
Matèries
Matèries (anglès)
Citació
Citació
CARPÉNÉ, Christian, et al. Insulin-mimetic compound hexaquis (benzylammonium) decavanadate is antilipolytic in human fat cells. World Journal of Diabetes. 2017. Vol. 8, num. 4, pags. 143-153. ISSN 1948-9358. [consulted: 30 of May of 2026]. Available at: https://hdl.handle.net/2445/158439